Lv71
4790 积分 2022-12-02 加入
POS0188 TARGETING COMPLEMENT FACTOR B (CFB) VIA A NOVEL SIRNA THERAPY (AZD6912) TO TREAT INFLAMMATORY ARTHRITIS
9小时前
已完结
Lipoprotein(a) and cardiovascular disease
2天前
已完结
A new alternative: inhibiting complement activation in patients with IgA nephropathy
1个月前
已完结
Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy
1个月前
已关闭
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
The role of complement in IgA nephropathy
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Drugs in Development to Treat IgA Nephropathy
1个月前
已完结
皖公网安备34019202002308
